All In MedTech

Device Trial Radar · NCT07920055

Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)

Sirolimus-Coated Balloon (SeQuent SCB) Versus Paclitaxel-Coated Balloon (RESTORE DEB) for Recurrent Coronary In-Stent Restenosis Following Prior Paclitaxel-Coated Balloon Therapy: A Multicenter, Randomized, Open-Label, Noninferiority Trial

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Aug 31, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Sir Run Run Shaw HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, multicenter, randomized, open-label, noninferiority trial will compare a sirolimus-coated balloon (SeQuent SCB) with a paclitaxel-coated balloon (RESTORE DEB) in 106 adults with recurrent coronary in-stent restenosis after prior paclitaxel-coated balloon treatment of the same segment. Participants will be randomized 1:1 to treatment of the target lesion with one of the study devices. The primary outcome is in-segment late lumen loss on quantitative coronary angiography 9 months after the index procedure. Clinical follow-up is scheduled at 30 days and 6, 9, and 12 months. Angiographic analysis and clinical event adjudication will be performed blinded to treatment assignment.

Conditions

  • Coronary In-stent Restenosis
  • Coronary Artery Disease

Interventions

  • SeQuent SCB sirolimus-coated balloonDevice

    Coronary balloon angioplasty of eligible target lesions

  • RESTORE DEB paclitaxel-coated balloonDrug

    Coronary balloon angioplasty of eligible target lesions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. In-Segment Late Lumen Loss at 9 MonthsTime frame: Immediately after index procedure and at 9 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sir Run Run Shaw Hospital

    Hangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.